Abstract 19P
Background
Triple-negaive breast cancer (TNBC) is a highly aggressive subtype with neoadjuvant options historically limited to chemotherapy until the recent success of the KEYNOTE-522 trial. Although TNBC is well known for being associated with constitutional pathogenic BRCA mutations when compared to other types of breast cancer, the genetic profiles of the patients in the KEYNOTE-522 trial are unknown and no subgroup analysis has assessed a possible relationship with treatment efficacy.
Methods
We analysed consecutive index-case genetic consults of TNBC patients (N = 170) between January 2020 and July 2024 in our oncogenetics department. Only patients with treatment history in our center were included. Tumor characteristics, pCR status and the type of chemotherapy agents used were collected. We compared the pCR and non pCR rates according to the genetic status and survival probability distribution stratified by the presence or not of Pembrolizumab and Carboplatin using Fisher’s exact test and the Kaplan-Meier method. A significance threshold of 5% was applied to all statistical analyses.
Results
A total of 132 patients were identified for the analysis. Significant benefits were observed in patients with pCR in terms of EFS (p = 0.001, HR = 0.07 CI 95% 0.02 – 0.21) and OS (p = 0.012, HR = 0.12 CI 95% 0.03 – 0.50), respectively. When comparing patients treated by a neoadjuvant chemotherapy regimen to those treated by pembrolizumab plus chemotherapy, a significantly higher pCR rate was observed with the latter group (p = 0.01). Regarding the presence of pathogenic variants (PV), the following were identified: BRCA1 (N = 10), BRCA2 (N = 3), PALB 2 (N = 1), PMS2 (N = 1), RAD51C (N = 3) and RAD51D (N = 1). 30 patients carried various variants of unknown significance. Notably, all patients carrying a BRCA PV treated with pembrolizumab achieved pCR but results were not statistically significant (p = 0.14).
Conclusions
To our knowledge this is the first descriptive analysis of the genetic landscape of patients with an indication for neoadjuvant Pembrolizumab. Interestingly, all patients carrying pathogenic variants of BRCA treated with pembrolizumab had pCR although results were not statistically significant compared to patients not presenting BRCA PV.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract